Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of serratia marcesens bacterial vaccine for preparing drug for treating lung fibrosis

A technology for Serratia marcescens and pulmonary fibrosis, applied in drug combinations, medical raw materials derived from bacteria, respiratory diseases, etc., can solve problems such as unsatisfactory effects and single effect

Inactive Publication Date: 2006-08-09
NAVY MEDICINE RES INST OF PLA
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although some scientists are committed to the direct application of antagonists of Th1 cytokines or Th2 cytokines for the prevention and treatment of pulmonary fibrosis, the effect is not satisfactory due to the single role

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Cultivation and collection of Serratia marcescens vaccine:

[0020] The working seeds for production are grown in solid state. After inoculating the working seeds for production in the nutrient agar medium, inoculate for 2 consecutive subcultures, and finally inoculate the slant of the nutrient agar medium in the Koch flask, and culture aerobically at 37°C for 19 hours, no more than 4 generations. During the cultivation, there is no special requirement on the cultivation conditions, whichever is suitable for the growth of the Serratia marcescens vaccine, the pH range is 2-9, and the temperature is 4-40°C. The pH value of this experiment is 6, and the temperature is 20°C. Microscopically inspect each bottle before collection, and discard those contaminated with bacteria. The collected bacterial lawn was placed in sterilized saline for injection, mixed thoroughly, and filtered with four layers of silk cloth. Measured according to the Chinese bacterial turbidity standar...

Embodiment 2

[0023] Get 1000ml of pyrogen-free deionized pure distilled water to dissolve 640mg of Serratia marcescens bacterin, mix evenly, sterilize and configure into 0.64mg / ml injection, bottle to make finished product.

Embodiment 3

[0025] The specific experiments and results are described as follows:

[0026] 1 Materials and methods

[0027] 1.1 Reagents and instruments Bleomycin (Pingyangmycin hydrochloride produced by Tianjin Hebei Pharmaceutical Factory, hereinafter referred to as BLM) was dissolved in normal saline to prepare 5 mg / ml.

[0028] 1.2 Animal grouping and treatment methods 80 healthy SD rats (provided by the Department of Experimental Zoology, Second Military Medical University), male or female, weighing (220±28) g. Among them, 48 rats were randomly divided into groups after intratracheal injection of BLMA55mg / kg at one time. ① Model group (24 rats): 0.3ml of normal saline was instilled into the nasal cavity of each rat from the next day after model preparation; ② Serratia marcescens vaccine group (24 rats): From the next day after model preparation, 0.3ml (0.01mg / kg) of Serratia marcescens vaccine was instilled into the nasal cavity of each rat every day for 28 days; ③Normal control gro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The present invention discloses an application of serratia marcescens vaccine in preparation of medicine for curing pulmonary fibrosis. The animal tests show that said serratia marcescens vaccine has obvious action for curing pulmonary fibrosis. As compared with hormone said serratia marcescens has incomparable safety.

Description

technical field [0001] The invention relates to the use of the Serratia marcescens bacterin, in particular to the use of the Serratia marcescens bacterin in the pharmaceutical field. Background technique [0002] The bacteriological characteristics of the Serratia marcescens bacterin and relevant information have been described in detail in the document disclosed in the CN02111996.1 patent. [0003] The bacterin is Gram-negative bacilli with flagella all over the body, motility, no encapsulation and spores. The bacterium grows well on ordinary medium at 37°C under general aerobic conditions. On ordinary agar plates, the colonies are smooth and moist. Raised, with neat edges and round shape, biochemical reaction: it can ferment glucose, sucrose, mannitol, amygdalin, produce acid but not gas. Non-fermentable rhamnose, arabinose, and closebiose. Can produce extracellular deoxyribonuclease. Species number: CGMCCNo.0744, classification name: Serratia marcescens. [0004] CN02...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/74A61P11/00
Inventor 靳小青何晓文钮燕王庆蓉沈越陆翠琴
Owner NAVY MEDICINE RES INST OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products